Filip Janku (Janku Filip)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 29

Top Topics

Squamous Cell Carcinoma

Hodgkin Lymphoma

Cell Proliferation

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Scientific reports

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer research communications 4 (2) (2024)
Filip Janku, Grace M Choong, Mateusz Opyrchal, Afshin Dowlati, Cinta Hierro, Jordi Rodon, Andreas Wicki, Martin D Forster, Sarah P Blagden, Jun Yin, Joel M Reid, Helene Muller, Natasa Cmiljanovic, Vladimir Cmiljanovic, Alex A Adjei
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors. Cancers 16 (6) (2024)
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer research communications 4 (2) (2024)
Filip Janku, Grace M Choong, Mateusz Opyrchal, Afshin Dowlati, Cinta Hierro, Jordi Rodon, Andreas Wicki, Martin D Forster, Sarah P Blagden, Jun Yin, Joel M Reid, Helene Muller, Natasa Cmiljanovic, Vladimir Cmiljanovic, Alex A Adjei
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors. Cancers 16 (6) (2024)
Aditya V Shreenivas, Filip Janku, Mohamed A Gouda, Hui-Zi Chen, Ben George, Shumei Kato, Razelle Kurzrock
ALK fusions in the pan-cancer setting: another tumor-agnostic target? NPJ precision oncology 7 (1) (2023)
Jason John Luke, Sarina A Piha-Paul, Theresa M Medina, Claire F Verschraegen, Mary Varterasian, Aoife M Brennan, Richard J Riese, Anna Sokolovska, James F Strauss, David L Hava, Filip Janku
Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jason John Luke, Sarina A Piha-Paul, Theresa M Medina, Claire F Verschraegen, Mary Varterasian, Aoife M Brennan, Richard J Riese, Anna Sokolovska, James F Strauss, David L Hava, Filip Janku
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. Cancer research communications (2023)
Kyaw Zin Thein, Amadeo B Biter, Kimberly C Banks, Andrew W Duda, Jennifer Saam, Jason Roszik, Filip Janku, Ferdinandos Skoulidis, John Victor Heymach, Edmund S Kopetz, Funda Meric-Bernstam, David S Hong
Identification of KRAS G12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO precision oncology 6 (2022)
Tito R Mendoza, David S Hong, Christine B Peterson, Bettzy Stephen, Ecaterina Dumbrava, Shubbam Pant, Apostolia Maria Tsimberidou, Timothy Anthony Yap, Ajay Sheshadri, Mehmet Altan, Goldy George, Lilibeth Castillo, Enedelia Rodriguez, Jing Gong, Vivek Subbiah, Filip Janku, Siqing Fu, Sarina A Piha-Paul, Jordi Rodon Ahnert, Daniel D Karp, Charles Cleeland, Funda Meric-Bernstam, Aung Naing
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Scientific reports 12 (1) (2022)
Filip Janku, Sae-Won Han, Toshihiko Doi, Alessio Amatu, Jaffer A Ajani, Yasutoshi Kuboki, Alex Cortez, Susan E Cellitti, Ping C Mahling, Kulandayan Subramanian, Heidi A Schoenfeld, Sarah M Choi, Lori A Iaconis, Lang Ho Lee, Marc R Pelletier, Glenn Dranoff, Vasileios Askoxylakis, Salvatore Siena
Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. Cancer immunology research 10 (12) (2022)
Filip Janku, Patricia LoRusso, Aaron S Mansfield, Rita Nanda, Alexander Spira, Tianli Wang, Amal Melhem-Bertrandt, Jennifer Sugg, Howard A Ball
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer. Investigational new drugs 39 (5) (2021)
Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Staal Rohrberg, Sant P Chawla, Filip Janku, David Schiff, Volker Heinemann, Yoshitaka Narita, Heinz-Josef Lenz, Masafumi Ikeda, Yuichi Ando, Wolfgang Wick, Joachim P Steinbach, Michael C Burger, Katharina Johanna Wenger, Ulrik N Lassen, Kamalesh K Sankhala, Cristiana Roggia, Isabelle Genvresse, Catya Munhoz, Christine Rentzsch, Susanne Reschke, Simon Langer, Markus Wagner, Stefan Kaulfuss, Charles Cai, Eleni Lagkadinou, Michael Jeffers, Carol Peña, Ghazaleh Tabatabai
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (10) (2021)
Jeffrey A How, Amir A Jazaeri, Pamela T Soliman, Nicole D Fleming, Jing Gong, Sarina A Piha-Paul, Filip Janku, Bettzy Stephen, Aung Naing
Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Scientific reports 11 (1) (2021)
Guowei Gu, Lin Tian, Sarah K Herzog, Yassine Rechoum, Luca Gelsomino, Meng Gao, Lili Du, Jin-Ah Kim, Derek Dustin, Hin Ching Lo, Amanda R Beyer, David G Edwards, Thomas Gonzalez, Anna Tsimelzon, Helen J Huang, Natalie M Fernandez, Sandra L Grimm, Susan G Hilsenbeck, Dan Liu, Jun Xu, Alyssa Alaniz, Shunqiang Li, Gordon B Mills, Filip Janku, Ralf Kittler, Xiang H F Zhang, Cristian Coarfa, Charles E Foulds, William Fraser Symmans, Sebastiano Andò, Suzanne A W Fuqua
Correction to: Hormonal modulation of ESR1 mutant metastasis. Oncogene (2021)
Joud Hajjar, Tito Mendoza, Liangliang Zhang, Siqing Fu, Sarina A Piha-Paul, David S Hong, Filip Janku, Daniel D Karp, Alexej Ballhausen, Jing Gong, Abdulrazzak Zarifa, Christine B Peterson, Funda Meric-Bernstam, Robert Jenq, Aung Naing
Associations between the gut microbiome and fatigue in cancer patients. Scientific reports 11 (1) (2021)
Filip Janku, Halle Huihong Zhang, Abdulmohammad Pezeshki, Sanjay Goel, Ravi Murthy, Andrea Wang-Gillam, Dale R Shepard, Thorunn Helgason, Tyler Masters, David S Hong, Sarina A Piha-Paul, Daniel D Karp, Mark G Klang, Steven Y Huang, Divya Sakamuri, Anjali Raina, Jean Torrisi, Stephen B Solomon, Alice Weissfeld, Ernest Trevino, Gary DeCrescenzo, Amanda Collins, Maria Miller, Jennifer L Salstrom, Ronald L Korn, Linping Zhang, Saurabh Saha, Alexey A Leontovich, David Tung, Brent L Kreider, Mary Varterasian, Khashayarsha Khazaie, Mrinal M Gounder
Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (1) (2020)
Yudong Wang, Filip Janku, Sarina Piha-Paul, Kenneth R Hess, Russell Broaddus, Lidong Liu, Naiyi Shi, Michael Overman, Scott Kopetz, Vivek Subbiah, Aung Naing, David Hong, Apostolia M Tsimberidou, Daniel Karp, James Yao, Siqing Fu
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Scientific reports 10 (1) (2020)
Omar Alhalabi, Andrew W Hahn, Pavlos Msaouel, Alexander Y Andreev-Drakhlin, Funda Meric-Bernstam, Aung Naing, Sarina Piha-Paul, Filip Janku, Shubham Pant, Timothy Anthony Yap, David S Hong, Siqing Fu, Daniel Karp, Matthew T Campbell, Hung Le, Amishi Y Shah, Nizar M Tannir, Arlene O Siefker-Radtke, Jianjun Gao, Jason Roszik, Vivek Subbiah
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Molecular cancer research : MCR 19 (3) (2020)
Filip Janku, Haeseong Park, S Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah, David S Hong, Aung Naing, Vivianne M Velez-Bravo, Tamara G Barnes, Fredrick B Hagemeister, Gerald S Falchook, Daniel D Karp, Jennifer J Wheler, Sarina A Piha-Paul, Ignacio Garrido-Laguna, Elizabeth J Shpall, Luis E Fayad, Sattva S Neelapu, Funda Meric-Bernstam, Razelle Kurzrock, Michelle A Fanale
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (21) (2020)
Filip Janku, Divya Sakamuri, Shumei Kato, Helen J Huang, S Greg Call, Aung Naing, Veronica R Holley, Sapna Pradyuman Patel, Rodabe N Amaria, Gerald S Falchook, Sarina A Piha-Paul, Ralph G Zinner, Apostolia-Maria Tsimberidou, David S Hong, Funda Meric-Bernstam
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer 127 (3) (2020)
Guowei Gu, Lin Tian, Sarah K Herzog, Yassine Rechoum, Luca Gelsomino, Meng Gao, Lili Du, Jin-Ah Kim, Derek Dustin, Hin Ching Lo, Amanda R Beyer, David G Edwards, Thomas Gonzalez, Anna Tsimelzon, Helen J Huang, Natalie M Fernandez, Sandra L Grimm, Susan G Hilsenbeck, Dan Liu, Jun Xu, Alyssa Alaniz, Shunqiang Li, Gordon B Mills, Filip Janku, Ralf Kittler, Xiang H F Zhang, Cristian Coarfa, Charles E Foulds, William Fraser Symmans, Sebastiano Andò, Suzanne A W Fuqua
Hormonal modulation of ESR1 mutant metastasis. Oncogene 40 (5) (2020)
Alexej Ballhausen, Jennifer J Wheler, Daniel D Karp, Sarina A Piha-Paul, Siqing Fu, Shubham Pant, Apostolia M Tsimberidou, David S Hong, Vivek Subbiah, Veronica R Holley, Helen J Huang, Abenaa M Brewster, Kimberly B Koenig, Nuhad K Ibrahim, Funda Meric-Bernstam, Filip Janku
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (5) (2020)
Seyed Pairawan, Kenneth R Hess, Filip Janku, Nora S Sanchez, Kenna R Mills Shaw, Cathy Eng, Senthilkumar Damodaran, Milind Javle, Ahmed O Kaseb, David S Hong, Vivek Subbiah, Siqing Fu, David R Fogelman, Victoria M Raymond, Richard B Lanman, Funda Meric-Bernstam
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (8) (2019)
Gerald S Falchook, Razelle Kurzrock, Hesham M Amin, Wenyuan Xiong, Siqing Fu, Sarina A Piha-Paul, Filip Janku, Ghazaleh Eskandari, Daniel V Catenacci, Manfred Klevesath, Rolf Bruns, Uz Stammberger, Andreas Johne, Friedhelm Bladt, Manja Friese-Hamim, Pascal Girard, Samer El Bawab, David S Hong
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (6) (2019)
Reva K Basho, Clinton Yam, Michael Gilcrease, Rashmi K Murthy, Thorunn Helgason, Daniel D Karp, Funda Meric-Bernstam, Kenneth R Hess, Vicente Valero, Constance Albarracin, Jennifer K Litton, Mariana Chavez-MacGregor, David Hong, Razelle Kurzrock, Gabriel N Hortobagyi, Filip Janku, Stacy L Moulder
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. The oncologist 23 (11) (2018)
Winnie S Liang, Jo-Anne Vergilio, Bodour Salhia, Helen J Huang, Yasuhiro Oki, Ignacio Garrido-Laguna, Haeseong Park, Jason R Westin, Funda Meric-Bernstam, David Fabrizio, Vincent A Miller, Philip J Stephens, Michelle A Fanale, Jeffrey S Ross, Filip Janku
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. The oncologist 24 (2) (2018)
Minny Bhatty, Shumei Kato, Sarina A Piha-Paul, Aung Naing, Vivek Subbiah, Helen J Huang, Daniel D Karp, Apostolia M Tsimberidou, Ralph G Zinner, Wen-Jen Hwu, Milind M Javle, Sapna P Patel, Mimi I Hu, Gauri R Varadhachary, Anthony P Conley, Nishma M Ramzanali, Veronica R Holley, Razelle Kurzrock, Funda Meric-Bernstam, Young Kwang Chae, Kevin B Kim, Gerald S Falchook, Filip Janku
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer 125 (3) (2018)
Amita Patnaik, Michael Gordon, Frank Tsai, Kyriakos P Papadopoulos, Drew Rasco, Muralidhar Beeram, Siqing Fu, Filip Janku, Scott M Hynes, Sushma R Gundala, Melinda D Willard, Wei Zhang, Aimee Bence Lin, David S Hong
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer chemotherapy and pharmacology 82 (3) (2018)